Recent

% | $
Quotes you view appear here for quick access.

công ty Questcor Pharmaceuticals Message Board

  • maxdad01 maxdad01 Mar 26, 2013 2:04 PM Flag

    JUST OUT---MORE FROM S.A.

    PART 1
    Questcor Pharmaceuticals (QCOR) is a classic example of stock that moves independently of its company. Its performance in the market is largely dictated by mere speculation instead of its financial position. Despite the company's strong financial profile, its current share price is substantially below 52-week highs. The company suffered a major blow when Citron made a press release on Questcor's flagship product, Acthar Gel. The press release broke the news about AETNA's decision to delist Acthar Gel from its list of reimbursable drugs for all indications except infantile spasms.

    The news came in the wake of increasing sales and robust growth. However, panicked investors paid little attention to the present financial standings of the company, but traded based on the negative impact of the news. It has been six months now, since the news was released and there are still no signs of weakening sales. Instead, the year-end reports showed that the company became much stronger than before.

    Immediately after the major plunge last September 2012, the stock prices gradually bounced back and partially recovered as investors' confidence was lifted by encouraging financial results. However, the question remains whether the stock can fully recover to its peak level or not. This is a question that must be addressed before buying QCOR stocks. Let's look at the company's financial profile.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Great bullish article. Nice to see some earnings and balance sheet specifics.

      Sentiment: Strong Buy

    • No one answered yet the reason behind AETNA decision to delist ACTH ?

      • 12 Replies to mastershortseller
      • Can you read and comprehend? Do you know what an external appeal process is? Are you familiar with the requirement of pre-authorization? Do you know what information manipulation consists of? This you must know because you are one big perpetrator of this action. Stop masquerading around as a clear headed honesty providing purveyor of information...this you are not. Just a dishonest, subtle provider of misinformation...in other words a danged dishonest shorty. We know you for what you are. Innocence is not your true mantra.

        Sentiment: Strong Buy

      • Master, EPS shall clear all "confusion", I believe in EPS and FCF as the ultimate "confusion clearers". Investors think long term. Shorts think, what else, short term. I do think confusion may take a while longer to clear, therefore shorts enjoy your time in the sun, and beware of some PE firm enamored by QCOR's FCFs and pristine B/S coming in and bringing ultimate nightfall to all shorts.

      • How many times must a man turn his head, and pretend that he just don't see?
        The answer, my friend, is blowin' in the wind, the answer is blowin' in the wind.

      • LuvDat, I like that.
        thank you.
        But what about the other indications, why does AETNA not cover it. according to Mikey AETNA does cover case by case basis
        there is so much confusion

        in absence of clear conviction , shorts thrive and win.

        If everything is clear as black and white , shorts have no chance, but since so much confusion is around it , that is the main reason for pressure on PPS. SMART Money ( dumb money ) is managed by ignorant uneducated ppl. country is run by criminals and thugs. i don't need further explanation
        so unless util longs clear everything nothing is going to happen.

      • Aetna considers repository corticotropin (H.P. Acthar® Gel) medically necessary for West syndrome (infantile spasms)

        Aetna considers repository corticotropin not medically necessary for diagnostic testing of adrenocortical function because it has not been shown to be superior to cosyntropin for this purpose.

        Aetna considers repository corticotropin not medically necessary for corticosteroid-responsive conditions because it has not been proven to be more effective than corticosteroids for these indications.

        Aetna considers repository corticotropin experimental and investigational for all other indications because its effectiveness for these indications has not been established.

      • Citron scary... NOT

        Articles people write long or short.... usually just opinion and uneducated at that

        MasterShortSeller.... still afraid to send me an email and compare notes.

      • Strange Longs are resorting to foul language when the article they themselves posted SAYS:
        QUOTE
        he company suffered a major blow when Citron made a press release on Questcor's flagship product, Acthar Gel. The press release broke the news about AETNA's decision to delist Acthar Gel from its list of reimbursable drugs for all indications except infantile spasms.
        END OF QUOTE

        THe question was simple: AETNA's decision to delist Acthar Gel from its list of reimbursable drugs for all indications except infantile spasms ?

        Why ACTH got delisted except for IS ?

        please no need for shallow speech. we are all mature enough

      • Let me sum YOU up. A liar and information manipulator. You are a zero.
        Fe fi fo fum
        You smell like just what you are..#$%$.

        Sentiment: Strong Buy

      • blah blah blah Aetna, blah blah blah.

        blah blah blah Ginger blah blah blah

      • Come on, you should know it. One of your buddies said citron asked his Aetna friends to release the coverage news on YMB. I remember it is ILUVCORRUPTION

      • View More Messages
 
QCOR
0.00(0.00%)